Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Oilminerdeluxeon Feb 12, 2023 1:23pm
223 Views
Post# 35282113

RE:RE:" Missing 18 Pending patients data"

RE:RE:" Missing 18 Pending patients data"When reading that, oh man. Hope the smart folks on the board lends a few minutes to discuss it (I need to digest the talk tomorrow while at work, when the boss is not around). Mind-boggling if so many patients are left to influence the CR in a positive way. And there is nothing that points to them having much different outcome from those already done. I apologize if I have misunderstood the whole post. If not, well, I think I have to sell that damn kidney and load up with every cent left to spare. I mean if half of those still in waiting are CR, that should bring extremely happy days to shareholders. Hmm, perhaps that's why our CEO spoke of possible j/v talk late 2023 or beginning of 2024? There is simply a bit more time to pass until there are 25 optimized patients completed? I hope I have not unwillingly set myself up for disappointment now. I guess I can always blame my lack of English skill or low IQ. Made the day a bit more interesting at least.
<< Previous
Bullboard Posts
Next >>